Full-Time

Thought Leader Liaison

Pulmonology

Posted on 10/6/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$200k - $230k/yr

+ Bonus

Nashville, TN, USA + 3 more

More locations: Chicago, IL, USA | Memphis, TN, USA | Kansas City, MO, USA

In Person

Business travel is regularly required (50% - 65%). Located near a hub airport is recommended.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Sales
Marketing
Requirements
  • 8+ years of experience in pharmaceutical, biotech or related industry in customer facing roles
  • 5+ years of experience in thought leader engagement; medical affairs, marketing, sales/sales leadership or clinical experience
  • 3+ years working within Pulmonology
  • Experience developing and executing HCP key strategies
  • Proven ability to develop and execute KOL mapping and plans, as well as building KOL advocacy in the targeted therapeutic areas
  • Clinical, technical, and scientific knowledge and proficiency in complex disease states
  • Existing relationships with KOLs (opinion leaders, centers of excellence etc.)
  • Strong relationship building skills, with proven ability to build and maintain lasting relationships with KOLs and navigate strategic accounts (Integrated Delivery Networks, Academic Medical Centers, Centers of Excellence, etc.)
  • Ability to exercise strong decision-making skills and live up to the highest ethical standards
  • Excellent written and verbal communication skills including confident executive presence
  • Ability to build productive partnerships and collaborate effectively in a matrix organization
  • Ability to creatively address problems in an organized, systematic way
  • High degree of organizational awareness, ability to connect the dots to understand all the interdependency and big picture
  • Exceptional critical thinking to help identify educational gaps, analyze findings, and make recommendations while articulating next steps
  • Strong understanding of legal and regulatory environment in pharmaceutical promotional activities, pharma industry guidelines and other compliance-related issues
  • Bachelor’s degree
  • MBA or advanced degree desired but not required
Responsibilities
  • Identify, cultivate, and maintain professional relationships with established and up-and-coming regional Key Opinion Leaders in targeted specialties
  • Support deep engagement of KOLs (ex. Navigating IDNs / Centers of Excellence, Professional Organizations)
  • Identify, map, and manage relationships with key national associations and other large treatment facilities (includes the detailed mapping of referral patterns, key relationships, and influencers)
  • Coordinate and lead one-to-one exchanges between Mallinckrodt team and KOLs across key initiatives and events
  • Attend and manage brand activity at key regional and targeted national conferences (may encompass Rheumatology, Nephrology, Pulmonology, Ophthalmology)
  • Manage overall regional sponsorships including working with organizations to secure sponsorships, and owning regional congress plan
  • Coordinate executive meetings with KOLs at national conferences
  • Support all necessary conference and speaker contract requirements in a timely manner
  • Coordinate with marketing to ensure all congress materials are delivered on time
  • Work cross functionally to drive and develop aligned external engagement strategies across multiple cross functional teams including medical, training, marketing, and sales
  • Coordinate closely with the sales team to ensure alignment with conference KOL engagement plan as well as other KOL/account engagement
  • Provide market insights back to the marketing team and provide input into P2P development, advisory boards, and strategy
  • Be a resource for the Marketing team to develop board strategy, content, advisory recommendations, and attend advisory boards as appropriate
  • Coordinate with Market Development Manager and Speaker Programs Management on KOL Speaker bureau relationships including supporting speaker training
  • Provide insights summary from key congresses to the marketing team
Desired Qualifications
  • Extensive field travel required

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE